Suppr超能文献

60月龄及以下泰国儿童队列中季节性流感灭活疫苗接种的成本效益

Cost-effectiveness of inactivated seasonal influenza vaccination in a cohort of Thai children ≤60 months of age.

作者信息

Kittikraisak Wanitchaya, Suntarattiwong Piyarat, Ditsungnoen Darunee, Pallas Sarah E, Abimbola Taiwo O, Klungthong Chonticha, Fernandez Stefan, Srisarang Suchada, Chotpitayasunondh Tawee, Dawood Fatimah S, Olsen Sonja J, Lindblade Kim A

机构信息

Influenza Program, Thailand Ministry of Public Health - U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand.

Infectious Diseases Unit, Queen Sirikit National Institute of Child Health, Ministry of Public Health, Bangkok, Thailand.

出版信息

PLoS One. 2017 Aug 24;12(8):e0183391. doi: 10.1371/journal.pone.0183391. eCollection 2017.

Abstract

BACKGROUND

Vaccination is the best measure to prevent influenza. We conducted a cost-effectiveness evaluation of trivalent inactivated seasonal influenza vaccination, compared to no vaccination, in children ≤60 months of age participating in a prospective cohort study in Bangkok, Thailand.

METHODS

A static decision tree model was constructed to simulate the population of children in the cohort. Proportions of children with laboratory-confirmed influenza were derived from children followed weekly. The societal perspective and one-year analytic horizon were used for each influenza season; the model was repeated for three influenza seasons (2012-2014). Direct and indirect costs associated with influenza illness were collected and summed. Cost of the trivalent inactivated seasonal influenza vaccine (IIV3) including promotion, administration, and supervision cost was added for children who were vaccinated. Quality-adjusted life years (QALY), derived from literature, were used to quantify health outcomes. The incremental cost-effectiveness ratio (ICER) was calculated as the difference in the expected total costs between the vaccinated and unvaccinated groups divided by the difference in QALYs for both groups.

RESULTS

Compared to no vaccination, IIV3 vaccination among children ≤60 months in our cohort was not cost-effective in the introductory year (2012 season; 24,450 USD/QALY gained), highly cost-effective in the 2013 season (554 USD/QALY gained), and cost-effective in the 2014 season (16,200 USD/QALY gained).

CONCLUSION

The cost-effectiveness of IIV3 vaccination among children participating in the cohort study varied by influenza season, with vaccine cost and proportion of high-risk children demonstrating the greatest influence in sensitivity analyses. Vaccinating children against influenza can be economically favorable depending on the maturity of the program, influenza vaccine performance, and target population.

摘要

背景

接种疫苗是预防流感的最佳措施。我们在泰国曼谷进行了一项前瞻性队列研究,对60个月及以下儿童接种三价灭活季节性流感疫苗与不接种疫苗进行了成本效益评估。

方法

构建静态决策树模型以模拟队列中的儿童群体。实验室确诊流感儿童的比例来自每周随访的儿童。每个流感季节采用社会视角和一年的分析期限;该模型在三个流感季节(2012 - 2014年)重复使用。收集并汇总与流感疾病相关的直接和间接成本。对于接种疫苗的儿童,增加了包括推广、接种和监督成本在内的三价灭活季节性流感疫苗(IIV3)成本。从文献中获取的质量调整生命年(QALY)用于量化健康结果。增量成本效益比(ICER)计算为接种组和未接种组预期总成本的差异除以两组QALY的差异。

结果

与不接种疫苗相比,我们队列中60个月及以下儿童接种IIV3疫苗在引入年(2012年季节;每获得1个QALY花费24,450美元)不具有成本效益,在2013年季节具有高成本效益(每获得1个QALY花费554美元),在2014年季节具有成本效益(每获得1个QALY花费16,200美元)。

结论

参与队列研究的儿童接种IIV3疫苗的成本效益因流感季节而异,在敏感性分析中,疫苗成本和高危儿童比例显示出最大影响。根据项目成熟度、流感疫苗性能和目标人群,为儿童接种流感疫苗在经济上可能是有利的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda3/5570265/6f9f925e27b5/pone.0183391.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验